Post-marketing case literature includes rare descriptions of peripheral neuropathy temporally associated with alirocumab, and pharmacovigilance analyses have noted disproportionality signals for some neuropsychiatric terms with PCSK9 inhibitors; however, spontaneous reports lack denominators, have channeling bias, and cannot adjudicate causality, while confounding by comorbidity, concomitant statins, diabetes, or B-12 status is common [3,15,208]. This evidence concerns the gene PCSK9 and peripheral neuropathy.